AI Article Synopsis
- The study investigates how endometrial cancer recurs in patients who initially showed no residual tumors after surgery and chemotherapy.
- A total of 640 patients were analyzed, revealing that most Type I and Type II cancers experienced early recurrence within 2 years, with high mortality rates after recurrence.
- Conclusions suggest that the majority of recurrences happen shortly after treatment, regardless of the cancer's clinical stage or type.
Article Abstract
Background/aim: Initial treatment of endometrial cancer with surgery and platinum and taxane-based chemotherapy is often successful, but it remains unclear as to whether certain types of the disease relapse. The aim of this study was to identify the clinical features of recurrence in patients without residual tumour in endometrial cancer.
Patients And Methods: Clinical features, histological type, and time to recurrence were analyzed in 640 endometrial cancer patients without residual tumours.
Results: Of 640 patients, 517 were type I and 123 were type II. For type I, early recurrent (ER) disease and late recurrent (LR) disease were noted in 80 and 8 patients, respectively, and 97.5% of ER occurred within 2 years. After recurrence, 76.2% of ER and 50% of LR patients died. In type II, ER and LR were noted in 41 and 1 patients, respectively, and 97.6% of ER occurred within 2 years, of which 75.6% died after recurrence. One LR case died of disease.
Conclusion: Most patients recurred within 2 years irrespective of clinical stage or type.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.13637 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!